APO RESEARCH · REPORT
PARP (Poly ADP-Ribose Polymerase) Inhibitor
PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).
Product & engineering
Understand the product.
PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).
They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.
In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.
Selected research
Industry Research
PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Research Report 2026
Market perspective
PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).
They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.
In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.
Read the full market overview
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor key players include AstraZeneca, Tesaro, Merck & Co, etc. Global top three manufacturers hold a share about 90%.
North America is the largest market, with a share about 70%, followed by Europe and Emerging Country, both have a share about 25 percent.
In terms of product, Lynparza is the largest segment, with a share over 65%. And in terms of application, the largest application is Ovarian Cancer, followed by Breast Cancer.
Report Scope
This report quantifies the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
PARP (Poly ADP-Ribose Polymerase) Inhibitor Market by Company
AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer
GSK
Zai Lab
PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Type
Lynparza
Zejula
Rubraca
Talzenna
Other
PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Application
Ovarian Cancer
Breast Cancer
Other
PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PARP (Poly ADP-Ribose Polymerase) Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PARP (Poly ADP-Ribose Polymerase) Inhibitor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of PARP (Poly ADP-Ribose Polymerase) Inhibitor by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of PARP (Poly ADP-Ribose Polymerase) Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Lynparza
- Zejula
- Rubraca
- Talzenna
- Other
Applications
- Ovarian Cancer
- Breast Cancer
- Other
Companies covered
- AstraZeneca
- Tesaro
- Merck & Co
- Clovis Oncology
- Pfizer
- GSK
- Zai Lab
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size (2021-2032)
- 2.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (2021-2032)
- 2.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Average Price (2021-2032)
- 2.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Lynparza
- 2.3.3 Zejula
- 2.3.4 Rubraca
- 2.3.5 Talzenna
- 2.3.6 Other
- 2.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Ovarian Cancer
- 2.4.3 Breast Cancer
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue of Manufacturers (2021-2026)
- 3.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Manufacturers (2021-2026)
- 3.5 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Product Type & Application
- 3.8 Global Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Established Date
- 3.9 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 AstraZeneca
- 4.1.1 AstraZeneca Company Information
- 4.1.2 AstraZeneca Business Overview
- 4.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
- 4.1.5 AstraZeneca Recent Developments
- 4.2 Tesaro
- 4.2.1 Tesaro Company Information
- 4.2.2 Tesaro Business Overview
- 4.2.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
- 4.2.5 Tesaro Recent Developments
- 4.3 Merck & Co
- 4.3.1 Merck & Co Company Information
- 4.3.2 Merck & Co Business Overview
- 4.3.3 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
- 4.3.5 Merck & Co Recent Developments
- 4.4 Clovis Oncology
- 4.4.1 Clovis Oncology Company Information
- 4.4.2 Clovis Oncology Business Overview
- 4.4.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
- 4.4.5 Clovis Oncology Recent Developments
- 4.5 Pfizer
- 4.5.1 Pfizer Company Information
- 4.5.2 Pfizer Business Overview
- 4.5.3 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
- 4.5.5 Pfizer Recent Developments
- 4.6 GSK
- 4.6.1 GSK Company Information
- 4.6.2 GSK Business Overview
- 4.6.3 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
- 4.6.5 GSK Recent Developments
- 4.7 Zai Lab
- 4.7.1 Zai Lab Company Information
- 4.7.2 Zai Lab Business Overview
- 4.7.3 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
- 4.7.5 Zai Lab Recent Developments
5 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Scenario by Region
- 5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region: 2021-2032
- 5.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region: 2021-2026
- 5.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region: 2027-2032
- 5.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region: 2021-2032
- 5.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region: 2021-2026
- 5.3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region: 2027-2032
- 5.4 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Country
- 5.4.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021-2032)
- 5.4.3 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Country
- 5.5.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021-2032)
- 5.5.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Country
- 5.6.1 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021-2032)
- 5.6.3 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Country
- 5.7.1 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021-2032)
- 5.7.3 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Country
- 5.8.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021-2032)
- 6.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021-2032) & (k units)
- 6.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2021-2032)
- 6.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2021-2032)
- 6.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2021-2032)
- 6.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021-2032)
- 7.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021-2032) & (k units)
- 7.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2021-2032)
- 7.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2021-2032)
- 7.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2021-2032)
- 7.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Value Chain Analysis
- 8.1.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Mode & Process
- 8.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors
- 8.2.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Customers
9 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Analyzing Market Dynamics
- 9.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Trends
- 9.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Drivers
- 9.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Opportunities and Challenges
- 9.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst